166 related articles for article (PubMed ID: 34882774)
1. Protease-stable DARPins as promising oral therapeutics.
Simeon RA; Zeng Y; Chonira V; Aguirre AM; Lasagna M; Baloh M; Sorg JA; Tommos C; Chen Z
Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34882774
[TBL] [Abstract][Full Text] [Related]
2. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
3. Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
Peng Z; Simeon R; Mitchell SB; Zhang J; Feng H; Chen Z
mSphere; 2019 Oct; 4(5):. PubMed ID: 31578248
[No Abstract] [Full Text] [Related]
4. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.
Wang S; Zhu D; Sun X
Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336
[TBL] [Abstract][Full Text] [Related]
5. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
Zhang Y; Yang Z; Gao S; Hamza T; Yfantis HG; Lipsky M; Feng H
Anaerobe; 2017 Dec; 48():249-256. PubMed ID: 29031928
[TBL] [Abstract][Full Text] [Related]
6. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
[TBL] [Abstract][Full Text] [Related]
7. Study of the frequency of Clostridium difficile tcdA, tcdB, cdtA and cdtB genes in feces of Calves in south west of Iran.
Doosti A; Mokhtari-Farsani A
Ann Clin Microbiol Antimicrob; 2014 Jun; 13():21. PubMed ID: 24903619
[TBL] [Abstract][Full Text] [Related]
8. Human α-Defensin-6 Neutralizes
Barthold L; Heber S; Schmidt CQ; Gradl M; Weidinger G; Barth H; Fischer S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562899
[TBL] [Abstract][Full Text] [Related]
9. Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile.
Aminzadeh A; Tiwari MK; Mamah Mustapha SS; Navarrete SJ; Henriksen AB; Møller IM; Krogfelt KA; Bjerrum MJ; Jørgensen R
Free Radic Biol Med; 2020 Nov; 160():433-446. PubMed ID: 32860983
[TBL] [Abstract][Full Text] [Related]
10. Human peptide α-defensin-1 interferes with Clostridioides difficile toxins TcdA, TcdB, and CDT.
Fischer S; Ückert AK; Landenberger M; Papatheodorou P; Hoffmann-Richter C; Mittler AK; Ziener U; Hägele M; Schwan C; Müller M; Kleger A; Benz R; Popoff MR; Aktories K; Barth H
FASEB J; 2020 May; 34(5):6244-6261. PubMed ID: 32190927
[TBL] [Abstract][Full Text] [Related]
11. Systematic Evaluation of Parameters Important for Production of Native Toxin A and Toxin B from
Aminzadeh A; Jørgensen R
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33801738
[TBL] [Abstract][Full Text] [Related]
12. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
[TBL] [Abstract][Full Text] [Related]
13. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
14. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B.
Mansfield MJ; Tremblay BJ; Zeng J; Wei X; Hodgins H; Worley J; Bry L; Dong M; Doxey AC
PLoS Pathog; 2020 Dec; 16(12):e1009181. PubMed ID: 33370413
[TBL] [Abstract][Full Text] [Related]
15. Low Density Lipoprotein Receptor-Related Protein-1 (LRP1) Is Involved in the Uptake of
Schöttelndreier D; Langejürgen A; Lindner R; Genth H
Front Cell Infect Microbiol; 2020; 10():565465. PubMed ID: 33194803
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.
Paparella AS; Aboulache BL; Harijan RK; Potts KS; Tyler PC; Schramm VL
Nat Commun; 2021 Nov; 12(1):6285. PubMed ID: 34725358
[TBL] [Abstract][Full Text] [Related]
17. A neutralizing antibody that blocks delivery of the enzymatic cargo of
Kroh HK; Chandrasekaran R; Zhang Z; Rosenthal K; Woods R; Jin X; Nyborg AC; Rainey GJ; Warrener P; Melnyk RA; Spiller BW; Lacy DB
J Biol Chem; 2018 Jan; 293(3):941-952. PubMed ID: 29180448
[No Abstract] [Full Text] [Related]
18. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.
Hussack G; Arbabi-Ghahroudi M; van Faassen H; Songer JG; Ng KK; MacKenzie R; Tanha J
J Biol Chem; 2011 Mar; 286(11):8961-76. PubMed ID: 21216961
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of
Raeisi H; Azimirad M; Asadzadeh Aghdaei H; Zarnani AH; Abdolalizadeh J; Yadegar A; Zali MR
Microbiol Spectr; 2023 Sep; 11(5):e0531022. PubMed ID: 37668373
[TBL] [Abstract][Full Text] [Related]
20. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
